These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 15128268)
1. Cellular effects of deoxynojirimycin analogues: uptake, retention and inhibition of glycosphingolipid biosynthesis. Mellor HR; Neville DC; Harvey DJ; Platt FM; Dwek RA; Butters TD Biochem J; 2004 Aug; 381(Pt 3):861-6. PubMed ID: 15128268 [TBL] [Abstract][Full Text] [Related]
2. Cellular effects of deoxynojirimycin analogues: inhibition of N-linked oligosaccharide processing and generation of free glucosylated oligosaccharides. Mellor HR; Neville DC; Harvey DJ; Platt FM; Dwek RA; Butters TD Biochem J; 2004 Aug; 381(Pt 3):867-75. PubMed ID: 15128289 [TBL] [Abstract][Full Text] [Related]
3. N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo. Andersson U; Butters TD; Dwek RA; Platt FM Biochem Pharmacol; 2000 Apr; 59(7):821-9. PubMed ID: 10718340 [TBL] [Abstract][Full Text] [Related]
4. Structure-Activity Studies of N-Butyl-1-deoxynojirimycin (NB-DNJ) Analogues: Discovery of Potent and Selective Aminocyclopentitol Inhibitors of GBA1 and GBA2. Gu X; Gupta V; Yang Y; Zhu JY; Carlson EJ; Kingsley C; Tash JS; Schönbrunn E; Hawkinson J; Georg GI ChemMedChem; 2017 Dec; 12(23):1977-1984. PubMed ID: 28975712 [TBL] [Abstract][Full Text] [Related]
5. Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses. Butters TD; Dwek RA; Platt FM Glycobiology; 2005 Oct; 15(10):43R-52R. PubMed ID: 15901676 [TBL] [Abstract][Full Text] [Related]
7. Glycolipid depletion in antimicrobial therapy. Svensson M; Frendeus B; Butters T; Platt F; Dwek R; Svanborg C Mol Microbiol; 2003 Jan; 47(2):453-61. PubMed ID: 12519195 [TBL] [Abstract][Full Text] [Related]
8. Ultrastructural changes in the Golgi apparatus and secretory granules of HL-60 cells treated with the imino sugar N-butyldeoxynojirimycin. Neises GR; Woodman PG; Butters TD; Ornberg RL; Platt FM Biol Cell; 1997 May; 89(2):123-31. PubMed ID: 9351192 [TBL] [Abstract][Full Text] [Related]
9. N -butyldeoxynojirimycin reduces growth and ganglioside content of experimental mouse brain tumours. Ranes MK; El-Abbadi M; Manfredi MG; Mukherjee P; Platt FM; Seyfried TN Br J Cancer; 2001 Apr; 84(8):1107-14. PubMed ID: 11308262 [TBL] [Abstract][Full Text] [Related]
10. Membrane disruption and cytotoxicity of hydrophobic N-alkylated imino sugars is independent of the inhibition of protein and lipid glycosylation. Mellor HR; Platt FM; Dwek RA; Butters TD Biochem J; 2003 Sep; 374(Pt 2):307-14. PubMed ID: 12769816 [TBL] [Abstract][Full Text] [Related]
12. Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease. Andersson U; Smith D; Jeyakumar M; Butters TD; Borja MC; Dwek RA; Platt FM Neurobiol Dis; 2004 Aug; 16(3):506-15. PubMed ID: 15262262 [TBL] [Abstract][Full Text] [Related]
13. New therapeutics for the treatment of glycosphingolipid lysosomal storage diseases. Butters TD; Dwek RA; Platt FM Adv Exp Med Biol; 2003; 535():219-26. PubMed ID: 14714898 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of glycogen breakdown by imino sugars in vitro and in vivo. Andersson U; Reinkensmeier G; Butters TD; Dwek RA; Platt FM Biochem Pharmacol; 2004 Feb; 67(4):697-705. PubMed ID: 14757169 [TBL] [Abstract][Full Text] [Related]
16. Imino sugars that are less toxic but more potent as antivirals, in vitro, compared with N-n-nonyl DNJ. Mehta A; Ouzounov S; Jordan R; Simsek E; Lu X; Moriarty RM; Jacob G; Dwek RA; Block TM Antivir Chem Chemother; 2002 Sep; 13(5):299-304. PubMed ID: 12630678 [TBL] [Abstract][Full Text] [Related]
17. Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations. Alfonso P; Pampín S; Estrada J; Rodríguez-Rey JC; Giraldo P; Sancho J; Pocoví M Blood Cells Mol Dis; 2005; 35(2):268-76. PubMed ID: 16039881 [TBL] [Abstract][Full Text] [Related]
18. Reduced inflammatory potential of peritoneal macrophages recruited in mice pretreated with a glycolipid synthesis inhibitor. Yohe HC; Kitzmiller TJ; Bement WJ; Dwyer BE; Sinclair JF Inflammopharmacology; 2006 Aug; 14(3-4):170-5. PubMed ID: 16983496 [TBL] [Abstract][Full Text] [Related]
19. Stemming the tide: glycosphingolipid synthesis inhibitors as therapy for storage diseases. Tifft CJ; Proia RL Glycobiology; 2000 Dec; 10(12):1249-58. PubMed ID: 11159916 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of glycosphingolipid biosynthesis does not impair growth or morphogenesis of the postimplantation mouse embryo. Brigande JV; Platt FM; Seyfried TN J Neurochem; 1998 Feb; 70(2):871-82. PubMed ID: 9453585 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]